- Home
- ABSI vs PROK Comparison
ABSI vs PROK Comparison
Compare ABSI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | PROK |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.6M | 417.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABSI | PROK |
|---|---|---|
| Price | $3.18 | $2.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $7.78 | $6.25 |
| AVG Volume (30 Days) | ★ 4.6M | 1.5M |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,815,000.00 | $744,000.00 |
| Revenue This Year | $40.12 | $471.74 |
| Revenue Next Year | $331.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.01 | $0.46 |
| 52 Week High | $6.33 | $7.13 |
Technical Indicators
Market Signals| Indicator | ABSI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 39.34 |
| Support Level | $2.71 | $2.04 |
| Resistance Level | $3.11 | $2.25 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 59.91 | 19.23 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.